{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_52614"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_52614","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"THE RXR AGONIST MSU-42011 IS EFFECTIVE FOR THE TREATMENT OF PRECLINICAL NF1-DEFICIENT MODELS","abstract":"Thesis (Ph.D.)--Michigan State University. Molecular, Cellular, and Integrative Physiology – Doctor of Philosophy, 2025","abstract_html":"Thesis (Ph.D.)--Michigan State University. Molecular, Cellular, and Integrative Physiology – Doctor of Philosophy, 2025","abstract_has_math":false,"creators":["Hung, Pei-Yu"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Mendes Leal, Ana Sofia","Liby, Karen","Gallo, Kathleen","Jamie, Jamie","Xiao, Hua","Andrechek, Eran"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-11-18T18:59:09Z","subjects":["Oncology"],"languages":["eng"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:52614","local:Hung_grad.msu_0128D_21578"],"render_values":[{"text":"etd:52614","href":null,"code":true},{"text":"local:Hung_grad.msu_0128D_21578","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/16fs-6x70","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/16fs-6x70","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_52614","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Mendes Leal, Ana Sofia","Liby, Karen","Gallo, Kathleen","Jamie, Jamie","Xiao, Hua","Andrechek, Eran"]},{"key":"dc:creator","label":"Author","values":["Hung, Pei-Yu"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["text","Electronic dissertations"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Oncology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:52614","local:Hung_grad.msu_0128D_21578","https://doi.org/doi:10.25335/16fs-6x70"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (Ph.D.)--Michigan State University. Molecular, Cellular, and Integrative Physiology – Doctor of Philosophy, 2025","Retinoid X receptors (RXRs) are nuclear receptors that act as ligand-dependent transcription factors by heterodimerizing with other nuclear receptors to regulate key signaling pathways influencing cancer progression. Activation of RXRs modulates cell proliferation, inflammation, and immune responses within the tumor microenvironment (TME), impacting tumor growth and immune surveillance. While RXR agonists like bexarotene have demonstrated clinical utility in cutaneous T cell lymphoma, their broader application in cancer immunomodulation is under active investigation. Our lab has synthesized novel RXR agonists, with my particular focus on MSU-42011, which has shown promising preclinical activity in modulating tumor-promoting immune cells and signaling pathways involved in cancer progression.Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of plexiform neurofibromas (PNFs), which may progress to malignant peripheral nerve sheath tumors (MPNSTs), aggressive sarcomas with limited treatment options. The MEK inhibitor selumetinib is FDA-approved for NF1-associated PNFs, but its efficacy against MPNSTs is modest and limited by toxicity. Given the prominent infiltration of tumor-promoting macrophages in NF1 lesions and their correlation with disease progression, targeting immune components of the TME presents a promising therapeutic avenue. This study evaluates the RXR agonist MSU-42011, alone and in combination with selumetinib, using NF1-deficient cell lines (bearing NF1, CDKN2A and TP53 deletions) and a syngeneic MPNST mouse model. In vivo, treatment with MSU-42011 significantly inhibited tumor growth, reduced pERK levels, indicating effective suppression of MAPK signaling. Selumetinib alone achieved similar reductions; however, the combination therapy resulted in greater effects. Immunophenotyping showed that MSU-42011 reduced tumor-promoting macrophages (CD206+ and CD163+) and FOXP3+ Tregs, while increasing activated CD8+ T cells, indicating a shift toward enhanced anti-tumor immunity. These effects were further strengthened by combination therapy. In vitro, conditioned media from NF1-deficient cells induced significant upregulation of pro-inflammatory cytokines and chemokines including IL-6, CCL2, and TNFα in human THP1 cells and murine bone marrow-derived macrophages (BMDMs). Treatment with MSU-42011 or/and selumetinib partially reversed this induction. These findings highlight the potential of RXR agonists to reshape the TME by reducing tumor-promoting immune cells and increasing activated T cells. The combination of MSU-42011 with MEK inhibition further enhances anti-tumor efficacy, offering a promising therapeutic strategy for NF1-associated tumors. However, this study is limited by the genetic heterogeneity of NF1 and the rapid tumor progression observed in syngeneic models, which may not fully capture the complexity of human disease or immune editing dynamics. To overcome these limitations, ongoing studies are utilizing transgenic Nf1 mouse models and RNA sequencing-based immune profiling to further define the mechanisms of RXR agonist activity and to explore their effects on additional immune populations. In conclusion, this work supports the development of RXR-targeted therapies, either alone or in combination with MEK inhibitors, as a novel treatment strategy for NF1-associated tumors. These preclinical findings provide a strong foundation for future clinical translation aimed at improving therapeutic outcomes for patients with NF1.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf","1 online resource (119 p.) : ill."]},{"key":"dc:title","label":"Title","values":["THE RXR AGONIST MSU-42011 IS EFFECTIVE FOR THE TREATMENT OF PRECLINICAL NF1-DEFICIENT MODELS"]}]}],"canonical_facts":{"dc:contributor":["Mendes Leal, Ana Sofia","Liby, Karen","Gallo, Kathleen","Jamie, Jamie","Xiao, Hua","Andrechek, Eran"],"dc:creator":["Hung, Pei-Yu"],"dc:date":["2025"],"dc:description":["Thesis (Ph.D.)--Michigan State University. Molecular, Cellular, and Integrative Physiology – Doctor of Philosophy, 2025","Retinoid X receptors (RXRs) are nuclear receptors that act as ligand-dependent transcription factors by heterodimerizing with other nuclear receptors to regulate key signaling pathways influencing cancer progression. Activation of RXRs modulates cell proliferation, inflammation, and immune responses within the tumor microenvironment (TME), impacting tumor growth and immune surveillance. While RXR agonists like bexarotene have demonstrated clinical utility in cutaneous T cell lymphoma, their broader application in cancer immunomodulation is under active investigation. Our lab has synthesized novel RXR agonists, with my particular focus on MSU-42011, which has shown promising preclinical activity in modulating tumor-promoting immune cells and signaling pathways involved in cancer progression.Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of plexiform neurofibromas (PNFs), which may progress to malignant peripheral nerve sheath tumors (MPNSTs), aggressive sarcomas with limited treatment options. The MEK inhibitor selumetinib is FDA-approved for NF1-associated PNFs, but its efficacy against MPNSTs is modest and limited by toxicity. Given the prominent infiltration of tumor-promoting macrophages in NF1 lesions and their correlation with disease progression, targeting immune components of the TME presents a promising therapeutic avenue. This study evaluates the RXR agonist MSU-42011, alone and in combination with selumetinib, using NF1-deficient cell lines (bearing NF1, CDKN2A and TP53 deletions) and a syngeneic MPNST mouse model. In vivo, treatment with MSU-42011 significantly inhibited tumor growth, reduced pERK levels, indicating effective suppression of MAPK signaling. Selumetinib alone achieved similar reductions; however, the combination therapy resulted in greater effects. Immunophenotyping showed that MSU-42011 reduced tumor-promoting macrophages (CD206+ and CD163+) and FOXP3+ Tregs, while increasing activated CD8+ T cells, indicating a shift toward enhanced anti-tumor immunity. These effects were further strengthened by combination therapy. In vitro, conditioned media from NF1-deficient cells induced significant upregulation of pro-inflammatory cytokines and chemokines including IL-6, CCL2, and TNFα in human THP1 cells and murine bone marrow-derived macrophages (BMDMs). Treatment with MSU-42011 or/and selumetinib partially reversed this induction. These findings highlight the potential of RXR agonists to reshape the TME by reducing tumor-promoting immune cells and increasing activated T cells. The combination of MSU-42011 with MEK inhibition further enhances anti-tumor efficacy, offering a promising therapeutic strategy for NF1-associated tumors. However, this study is limited by the genetic heterogeneity of NF1 and the rapid tumor progression observed in syngeneic models, which may not fully capture the complexity of human disease or immune editing dynamics. To overcome these limitations, ongoing studies are utilizing transgenic Nf1 mouse models and RNA sequencing-based immune profiling to further define the mechanisms of RXR agonist activity and to explore their effects on additional immune populations. In conclusion, this work supports the development of RXR-targeted therapies, either alone or in combination with MEK inhibitors, as a novel treatment strategy for NF1-associated tumors. These preclinical findings provide a strong foundation for future clinical translation aimed at improving therapeutic outcomes for patients with NF1.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."],"dc:format":["application/pdf","1 online resource (119 p.) : ill."],"dc:identifier":["etd:52614","local:Hung_grad.msu_0128D_21578","https://doi.org/doi:10.25335/16fs-6x70"],"dc:language":["eng"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Oncology"],"dc:title":["THE RXR AGONIST MSU-42011 IS EFFECTIVE FOR THE TREATMENT OF PRECLINICAL NF1-DEFICIENT MODELS"],"dc:type":["text","Electronic dissertations"]},"updated_at":"2026-11-18T18:59:09Z"}